Shots:

• NICE has recommended Ajovy in its final appraisal document (FAD) to prevent migraine in patients with chronic migraine who have not responded to at least three prior preventive drug treatments
• The recommendation is based on a dossier submitted to NICE for a single technology appraisal (STA). Following the issuance of the FAD- NICE will provide its formal guidance to the NHS
• Ajovy is the first and only anti-CGRP therapy- approved in the US and EU- indicated for the treatment of migraine- offering both quarterly and monthly dosing options and is currently under development in Japan by Otsuka- in accordance with a 2017 licensing agreement signed b/w the companies

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Teva